Geneva, Switzerland – 5 September 2017 – AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed the first tranche of its Series B financing round, raising €8 million (CHF 8.8 million). View PDF
/wp-content/uploads/2018/04/logo.jpg00canvax/wp-content/uploads/2018/04/logo.jpgcanvax2017-09-05 13:20:492018-03-14 16:02:28AMAL Therapeutics raises EUR 8 million (CHF 8.8 million) in first closing of Series B financing round
Each year, startup.ch launches the TOP 100 STARTUP AWARD in cooperation with the Handelszeitung and PME Magazine. From over 100.000 young companies, the 100 most innovative and promising Swiss startups are picked by top startup experts. On Wednesday 14th September 2016, Amal Therapeutics reached the top10, and was elected at the rank number 8 by […]
/wp-content/uploads/2018/04/logo.jpg00canvax/wp-content/uploads/2018/04/logo.jpgcanvax2016-09-14 13:57:332018-03-14 16:02:30TOP 100 STARTUP AWARD 2016: on 14th September, Amal Therapeutics reached the top 10
Amongst several applications within the four partner sites, 14 candidates have been shortlisted for the 2016 Global Healthcare Innovation Academy in Calgary. Amal Therapeutics represented by Jean-François Mayol, was selected in the top 6 innovations by the Grand Jury comprised of international and local experts in science, innovation, healthcare, business, IP and marketing. Amal Therapeutics […]
/wp-content/uploads/2018/04/logo.jpg00canvax/wp-content/uploads/2018/04/logo.jpgcanvax2016-08-25 13:57:302018-03-14 16:02:24Amal Therapeutics Wins 2d prize 2016 at Global Healthcare Innovation Academy (GHIA), Calgary
Geneva, Switzerland, July 5, 2016 – Amal Therapeutics announced today that part of its recent research findings about the enhancement of anti-tumor immune responses through optimized combination of adjuvant and cellpenetrating peptide based-vaccines, is available on-line on the Molecular Therapy website on Tuesday July 5, 2016. View PDF
Geneva, Switzerland, April 8, 2016 – Amal Therapeutics, a Swiss biotech start-up company developing and progressing therapeutic vaccines in oncology, today announced the appointment of Jean-Yves Bonnefoy as new Scientific Advisory Board (SAB) member. Dr. Bonnefoy will bring over 20 years experience in Biotechnology company leadership and therapeutic cancer vaccine development. View PDF
/wp-content/uploads/2018/04/logo.jpg00canvax/wp-content/uploads/2018/04/logo.jpgcanvax2016-04-08 11:08:192018-03-16 09:18:57Amal Therapeutics SA announces the appointment of Dr. Jean-Yves Bonnefoy as member of the Scientific Advisory Board
Geneva, Switzerland, and Ingelheim, Germany, March 30, 2016 – Amal Therapeutics (Amal) completes CHF 3 million (EUR 2.75 million) Series A financing round with Boehringer Ingelheim Venture Fund (BIVF) as cornerstone investors. VI Partners and High-Tech Gründerfonds also participated in the round which will help progress Amal’s cancer vaccines. View PDF
/wp-content/uploads/2018/04/logo.jpg00canvax/wp-content/uploads/2018/04/logo.jpgcanvax2016-03-30 11:07:422018-03-16 09:17:45Amal Therapeutics raises CHF 3 million in a Series A financing round
Geneva, Switzerland, March 8, 2016 – Amal Therapeutics, a Swiss biotech start-up company developing and progressing therapeutic vaccines in oncology, today announced that it received a grant from the Swiss Commission for Technology & Innovation (CTI) to validate immunotherapies combination treatments. View PDF
GENEVA, December 1, 2015 – Amal Therapeutics SA (“Amal”), a biotechnology company developing active immunotherapies, announced the issuance on November 17, 2015 of the US Patent number 9,187,534 entitled “MULTI-EPITOPIC VACCINE” by the US Patent and Trademark Office (USPTO). This patent covers Amal’s multi-epitopic vaccine technology platform and its use as immunotherapy for the treatment […]
/wp-content/uploads/2018/04/logo.jpg00canvax/wp-content/uploads/2018/04/logo.jpgcanvax2015-12-01 11:06:282018-03-16 09:26:57US Patent granted for Amal Therapeutics’ novel cancer vaccine technology platform
Geneva, Switzerland, October 27, 2015 – Amal Therapeutics SA (“Amal”), a biotechnology company active in cancer immunotherapy announced today the signature of an exclusive patent license agreement with the University of Minnesota for the use of a novel peptide with potent immunostimulatory properties. View PDF
/wp-content/uploads/2018/04/logo.jpg00canvax/wp-content/uploads/2018/04/logo.jpgcanvax2015-10-27 11:05:512018-03-16 09:28:03Amal Therapeutics announces the signature of an Exclusive Patent License Agreement with the University of Minnesota
Geneva, Switzerland, September 8, 2015 – Amal Therapeutics, a Geneva based start-up Biotech Company developing and progressing therapeutic vaccines in oncology, announced today that it signed research collaboration agreement with the Oslo University Hospital (OUH)-Radiumhospitalet (Dept of Cellular Therapy). The objective of the collaboration is to validate Amal Therapeutics lead vaccine candidate using human-cells functional […]
/wp-content/uploads/2018/04/logo.jpg00canvax/wp-content/uploads/2018/04/logo.jpgcanvax2015-09-08 11:05:152018-03-16 09:25:51Amal Therapeutics and the Oslo University Hospital announce research collaboration agreement for cancer immunotherapy validation
AMAL Therapeutics raises EUR 8 million (CHF 8.8 million) in first closing of Series B financing round
/in News /by canvaxGeneva, Switzerland – 5 September 2017 – AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed the first tranche of its Series B financing round, raising €8 million (CHF 8.8 million). View PDF
TOP 100 STARTUP AWARD 2016: on 14th September, Amal Therapeutics reached the top 10
/in News /by canvaxEach year, startup.ch launches the TOP 100 STARTUP AWARD in cooperation with the Handelszeitung and PME Magazine. From over 100.000 young companies, the 100 most innovative and promising Swiss startups are picked by top startup experts. On Wednesday 14th September 2016, Amal Therapeutics reached the top10, and was elected at the rank number 8 by […]
Amal Therapeutics Wins 2d prize 2016 at Global Healthcare Innovation Academy (GHIA), Calgary
/in News /by canvaxAmongst several applications within the four partner sites, 14 candidates have been shortlisted for the 2016 Global Healthcare Innovation Academy in Calgary. Amal Therapeutics represented by Jean-François Mayol, was selected in the top 6 innovations by the Grand Jury comprised of international and local experts in science, innovation, healthcare, business, IP and marketing. Amal Therapeutics […]
Amal Therapeutics to publish R&D outcomes in Molecular Therapy
/in News /by canvaxGeneva, Switzerland, July 5, 2016 – Amal Therapeutics announced today that part of its recent research findings about the enhancement of anti-tumor immune responses through optimized combination of adjuvant and cellpenetrating peptide based-vaccines, is available on-line on the Molecular Therapy website on Tuesday July 5, 2016. View PDF
Amal Therapeutics SA announces the appointment of Dr. Jean-Yves Bonnefoy as member of the Scientific Advisory Board
/in News /by canvaxGeneva, Switzerland, April 8, 2016 – Amal Therapeutics, a Swiss biotech start-up company developing and progressing therapeutic vaccines in oncology, today announced the appointment of Jean-Yves Bonnefoy as new Scientific Advisory Board (SAB) member. Dr. Bonnefoy will bring over 20 years experience in Biotechnology company leadership and therapeutic cancer vaccine development. View PDF
Amal Therapeutics raises CHF 3 million in a Series A financing round
/in News /by canvaxGeneva, Switzerland, and Ingelheim, Germany, March 30, 2016 – Amal Therapeutics (Amal) completes CHF 3 million (EUR 2.75 million) Series A financing round with Boehringer Ingelheim Venture Fund (BIVF) as cornerstone investors. VI Partners and High-Tech Gründerfonds also participated in the round which will help progress Amal’s cancer vaccines. View PDF
Amal Therapeutics receives CTI grant to evaluate immunotherapy combination treatments
/in News /by canvaxGeneva, Switzerland, March 8, 2016 – Amal Therapeutics, a Swiss biotech start-up company developing and progressing therapeutic vaccines in oncology, today announced that it received a grant from the Swiss Commission for Technology & Innovation (CTI) to validate immunotherapies combination treatments. View PDF
US Patent granted for Amal Therapeutics’ novel cancer vaccine technology platform
/in News /by canvaxGENEVA, December 1, 2015 – Amal Therapeutics SA (“Amal”), a biotechnology company developing active immunotherapies, announced the issuance on November 17, 2015 of the US Patent number 9,187,534 entitled “MULTI-EPITOPIC VACCINE” by the US Patent and Trademark Office (USPTO). This patent covers Amal’s multi-epitopic vaccine technology platform and its use as immunotherapy for the treatment […]
Amal Therapeutics announces the signature of an Exclusive Patent License Agreement with the University of Minnesota
/in News /by canvaxGeneva, Switzerland, October 27, 2015 – Amal Therapeutics SA (“Amal”), a biotechnology company active in cancer immunotherapy announced today the signature of an exclusive patent license agreement with the University of Minnesota for the use of a novel peptide with potent immunostimulatory properties. View PDF
Amal Therapeutics and the Oslo University Hospital announce research collaboration agreement for cancer immunotherapy validation
/in News /by canvaxGeneva, Switzerland, September 8, 2015 – Amal Therapeutics, a Geneva based start-up Biotech Company developing and progressing therapeutic vaccines in oncology, announced today that it signed research collaboration agreement with the Oslo University Hospital (OUH)-Radiumhospitalet (Dept of Cellular Therapy). The objective of the collaboration is to validate Amal Therapeutics lead vaccine candidate using human-cells functional […]